InicioEKSO • NASDAQ
add
Ekso Bionics Holdings Inc
Cierre anterior
0,67 $
Intervalo diario
0,66 $ - 0,70 $
Intervalo anual
0,66 $ - 3,13 $
Cap. bursátil
15,09 M USD
Volumen medio
99,75 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
(USD) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos | 4,13 M | -10,38 % |
Gastos operativos | 4,85 M | -10,01 % |
Ingresos netos | -2,07 M | 38,42 % |
Margen de beneficio neto | -50,18 | 31,30 % |
Beneficios por acción | — | — |
EBITDA | -2,23 M | 10,97 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
(USD) | sept 2024info | Cambio interanual |
---|---|---|
Efectivo y a corto plazo | 8,29 M | -16,55 % |
Activos totales | 29,21 M | -6,33 % |
Responsabilidades totales | 14,34 M | -9,96 % |
Patrimonio total | 14,87 M | — |
Acciones en circulación | 22,00 M | — |
Precio-valor contable | 0,99 | — |
Rentabilidad económica | -23,48 % | — |
Retorno sobre capital | -33,02 % | — |
Flujo de caja
Variación neta del flujo de caja
(USD) | sept 2024info | Cambio interanual |
---|---|---|
Ingresos netos | -2,07 M | 38,42 % |
Efectivo de operaciones | -2,28 M | 32,09 % |
Efectivo de inversión | -8,00 mil | 52,94 % |
Efectivo de financiación | 4,69 M | — |
Variación neta del flujo de caja | 2,41 M | 171,42 % |
Flujo de caja libre | -1,11 M | 57,80 % |
Información sobre la empresa
Ekso Bionics Holdings Inc. is a company that develops and manufactures powered exoskeleton bionic devices that can be strapped on as wearable robots to enhance the strength, mobility, and endurance of industrial workers and people experiencing paralysis and mobility issues after a brain injury, stroke, multiple sclerosis or spinal cord injury. They enable individuals with any amount of lower extremity weakness, including those who are paralyzed, to stand up and walk.
Ekso Bionics currently focuses in the health and industrial sectors.
The company's first commercially available health product was called EksoGT. Ekso Bionics is the original developer of HULC, now under military development by Lockheed Martin, and the current developers of EksoNR, which allows patients who are relearning to walk the ability to stand and take steps. In December 2022, Ekso Bionics acquired the Human Motion & Control business unit from Parker Hannifin which includes the Indego product line. This acquisition allowed Ekso Bionics to begin selling exoskeletons to those who have an SCI and want a personal exoskeleton to walk at home and in their community. Wikipedia
Director ejecutivo
Fundación
2005
Sitio web
Empleados
70